MDT

86.16

-0.16%↓

A

113.06

-1.43%↓

VEEV

170.81

-1.7%↓

HQY

81.44

-2.7%↓

PHR.US

9.02

+2.73%↑

MDT

86.16

-0.16%↓

A

113.06

-1.43%↓

VEEV

170.81

-1.7%↓

HQY

81.44

-2.7%↓

PHR.US

9.02

+2.73%↑

MDT

86.16

-0.16%↓

A

113.06

-1.43%↓

VEEV

170.81

-1.7%↓

HQY

81.44

-2.7%↓

PHR.US

9.02

+2.73%↑

MDT

86.16

-0.16%↓

A

113.06

-1.43%↓

VEEV

170.81

-1.7%↓

HQY

81.44

-2.7%↓

PHR.US

9.02

+2.73%↑

MDT

86.16

-0.16%↓

A

113.06

-1.43%↓

VEEV

170.81

-1.7%↓

HQY

81.44

-2.7%↓

PHR.US

9.02

+2.73%↑

Search

Charles River Laboratories International Inc

Aperta

SettoreSettore sanitario

166.67 0.23

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

164.86

Massimo

169.04

Metriche Chiave

By Trading Economics

Entrata

-332M

-277M

Vendite

-11M

994M

Margine di Profitto

-27.816

Dipendenti

18,300

EBITDA

730K

198M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+18.4% upside

Dividendi

By Dow Jones

Utili prossimi

6 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-78M

7.9B

Apertura precedente

166.44

Chiusura precedente

166.67

Notizie sul Sentiment di mercato

By Acuity

61%

39%

317 / 349 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Charles River Laboratories International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

6 apr 2026, 23:17 UTC

Utili

Samsung Forecasts Record First-Quarter Operating Profit

6 apr 2026, 23:00 UTC

Azioni calde

Stocks to Watch: Health Insurers, Mawson, Owlet

6 apr 2026, 22:13 UTC

I principali Market Mover

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

6 apr 2026, 21:46 UTC

Acquisizioni, Fusioni, Takeovers

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

6 apr 2026, 17:09 UTC

I principali Market Mover

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

6 apr 2026, 16:56 UTC

Principali Notizie su Eventi

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

6 apr 2026, 14:47 UTC

I principali Market Mover

Stereotaxis Shares Rise on FDA Clearance for Synchrony

7 apr 2026, 00:00 UTC

Principali Notizie su Eventi

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

6 apr 2026, 23:58 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

6 apr 2026, 23:50 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

6 apr 2026, 23:36 UTC

Discorsi di Mercato

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

6 apr 2026, 23:15 UTC

Discorsi di Mercato

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

6 apr 2026, 22:52 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

6 apr 2026, 22:52 UTC

Discorsi di Mercato

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

6 apr 2026, 22:14 UTC

Discorsi di Mercato

Correction to Live Cattle Futures Article

6 apr 2026, 20:56 UTC

Discorsi di Mercato

Mexican Private Consumption Fell in January -- Market Talk

6 apr 2026, 20:50 UTC

Discorsi di Mercato

Energy & Utilities Roundup: Market Talk

6 apr 2026, 20:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

6 apr 2026, 19:58 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

6 apr 2026, 19:58 UTC

Discorsi di Mercato

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

6 apr 2026, 19:11 UTC

Discorsi di Mercato

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

6 apr 2026, 19:06 UTC

Discorsi di Mercato

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

6 apr 2026, 19:03 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

6 apr 2026, 19:03 UTC

Discorsi di Mercato

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

6 apr 2026, 18:36 UTC

Acquisizioni, Fusioni, Takeovers

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 apr 2026, 17:59 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

6 apr 2026, 17:13 UTC

Acquisizioni, Fusioni, Takeovers

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 apr 2026, 16:33 UTC

Discorsi di Mercato

Oil Futures Steady as Market Awaits Trump -- Market Talk

6 apr 2026, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

6 apr 2026, 14:59 UTC

Utili

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Confronto tra pari

Modifica del prezzo

Charles River Laboratories International Inc Previsione

Obiettivo di Prezzo

By TipRanks

18.4% in crescita

Previsioni per 12 mesi

Media 205.89 USD  18.4%

Alto 265 USD

Basso 175 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

8

Acquista

3

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

117.16 / 144.77Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

317 / 349 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat